Meningococcal Disease


PUBLISHED: 2017 CATEGORY: TYPE: External Link Mise à jour sur la vaccination contre la méningococcie invasive chez les enfants et les adolescents canadiens

Mise à jour sur la vaccination contre la méningococcie invasive chez les enfants et les adolescents canadiens

La méningococcie invasive (MI) est une maladie grave qui est souvent à l’origine d’un sepsis fulminant ou d’une méningite. Au Canada, elle est surtout attribuable aux sérogroupes B et C. Des programmes de vaccination systématique contre le méningocoque du sérogroupe C sont prévus à l’âge de 12 mois, et dans certaines régions sociosanitaires, le calendrier comprend l’administration de doses supplémentaires aux enfants plus jeunes. Les adolescents reçoivent systématiquement une dose de rappel du vaccin contre le sérogroupe C ou d’un vaccin quadrivalent (sérogroupes A, C, W et Y). L’utilisation systématique des vaccins contre le sérogroupe B n’est pas recommandée tant qu’on n’aura pas recueilli de données supplémentaires sur l’efficacité des vaccins sur le marché et la durée de la protection qu’ils confèrent. Cependant, les enfants d’au moins deux mois qui courent un risque accru de MI devraient être vaccinés contre les sérogroupes B et C dans les plus brefs délais.

Meningococcal infection is serious, often resulting in fulminant sepsis or meningitis. There are two main types of meningococcal conjugate vaccine currently available in Canada: serotype C meningococcal conjugate, and quadrivalent conjugate for serotypes A, C, Y, and W-135. The immunological characteristics that inform ongoing immunization policies, as well as some of the limits of current knowledge, are presented.
Meningococcal infection is serious, often resulting in fulminant sepsis or meningitis. There are two main types of meningococcal conjugate vaccine currently available in Canada: serotype C meningococcal conjugate, and quadrivalent conjugate for serotypes A, C, Y, and W-135. The immunological characteristics that inform ongoing immunization policies, as well as some of the limits of current knowledge, are presented.
Meningococcal infection is serious, often resulting in fulminant sepsis or meningitis. There are two main types of meningococcal conjugate vaccine currently available in Canada: serotype C meningococcal conjugate, and quadrivalent conjugate for serotypes A, C, Y, and W-135. The immunological characteristics that inform ongoing immunization policies, as well as some of the limits of current knowledge, are presented.
Authors: Robinson J
Corporate Authors: Comité des maladies infectieuses et d'immunisation
Publisher: Société canadienne de pédiatrie

PUBLISHED: 2017 CATEGORY: Health care providers TYPE: External Link Recent Progress in the Prevention of Serogroup B Meningococcal Disease

Recent Progress in the Prevention of Serogroup B Meningococcal Disease

The widespread use of meningococcal polysaccharide conjugate vaccines has highlighted the challenge of providing protection against serogroup B disease. Over a period of 4 decades, vaccine development has focused on subcapsular protein antigens, first with outer membrane vesicle (OMV) vaccines against epidemic outbreaks, and more recently on new multicomponent vaccines designed to offer better cross-protection against the antigenically diverse strains responsible for endemic disease. Because of the low incidence of meningococcal disease, the protective efficacy of these vaccines has not been determined in clinical studies, and their licensure has been based on serological data; however, the serological assays used to predict protective coverage have limitations. As a result, evidence of the effectiveness of these vaccines against different strains and the contribution of specific antigens to protection can only be provided by epidemiological analyses following their implementation in sufficiently large populations.

Authors: Feavers IM, Maiden MCJ
Journal Title: Clinical and Vaccine Immunology
Journal Volume: 24
Publisher: American Society for Microbiology

PUBLISHED: 2017 CATEGORY: Health care providers TYPE: External Link Update on invasive meningococcal vaccination for Canadian children and youth (CPS Position Statement)

Update on invasive meningococcal vaccination for Canadian children and youth (CPS Position Statement)

Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least two months of age. 

Meningococcal infection is serious, often resulting in fulminant sepsis or meningitis. There are two main types of meningococcal conjugate vaccine currently available in Canada: serotype C meningococcal conjugate, and quadrivalent conjugate for serotypes A, C, Y, and W-135. The immunological characteristics that inform ongoing immunization policies, as well as some of the limits of current knowledge, are presented.
Meningococcal infection is serious, often resulting in fulminant sepsis or meningitis. There are two main types of meningococcal conjugate vaccine currently available in Canada: serotype C meningococcal conjugate, and quadrivalent conjugate for serotypes A, C, Y, and W-135. The immunological characteristics that inform ongoing immunization policies, as well as some of the limits of current knowledge, are presented.
Meningococcal infection is serious, often resulting in fulminant sepsis or meningitis. There are two main types of meningococcal conjugate vaccine currently available in Canada: serotype C meningococcal conjugate, and quadrivalent conjugate for serotypes A, C, Y, and W-135. The immunological characteristics that inform ongoing immunization policies, as well as some of the limits of current knowledge, are presented.
Authors: Robinson J
Corporate Authors: Infectious Diseases and Immunization Committee
Publisher: Canadian Paediatric Society

PUBLISHED: 2017 CATEGORY: Parents, Adults TYPE: External Link What would happen if we stopped vaccinations?

What would happen if we stopped vaccinations?

Emphasizes that while vaccination programs have eliminated or significantly reduced many vaccine-preventable diseases, these diseases still exist and can once again become common and deadly if vaccination coverage does not continue at high levels.

Corporate Authors: Centers for Disease Control and Prevention
Publisher: Centers for Disease Control and Prevention

PUBLISHED: 2016 CATEGORY: TYPE: External Link Couverture vaccinale des enfants canadiens : points saillants de l'Enquête nationale sur la couverture vaccinale des enfants de 2013 (ENCVE)

Couverture vaccinale des enfants canadiens : points saillants de l'Enquête nationale sur la couverture vaccinale des enfants de 2013 (ENCVE)

L’Enquête nationale sur la couverture vaccinale des enfants (ENCVE) de 2013 constitue la plus grande enquête sur la couverture vaccinale nationale au Canada. Ses résultats indiquent que la majorité des enfants canadiens sont immunisés contre les maladies évitables par la vaccination, mais qu'on peut améliorer la situation en ce qui a trait aux doses de rappel.

Corporate Authors: Agence de la santé publique du Canada
Publisher: Agence de la santé publique du Canada

PUBLISHED: 2016 CATEGORY: Health care providers TYPE: External Link Vaccine coverage in Canadian children: Highlights from the 2013 childhood National Immunization Coverage Survey (cNICS)

Vaccine coverage in Canadian children: Highlights from the 2013 childhood National Immunization Coverage Survey (cNICS)

The 2013 Childhood National Immunization Coverage Survey (cNICS) is the largest national-level immunization coverage survey ever carried out in Canada. Results from the survey showed that the majority of Canadian children are immunized against vaccine-preventable diseases, but there is room to improve in keeping vaccinations up to date.

Corporate Authors: Public Health Agency of Canada
Publisher: Public Health Agency of Canada

PUBLISHED: 2016 CATEGORY: TYPE: External Link Votre histoire : Fondation canadienne de recherche sur le méningite

Votre histoire : Fondation canadienne de recherche sur le méningite

Faire part de votre expérience personnelle en envoyant votre histoire à la Fondation canadienne de recherche sur la méningite.

Authors: Fondation canadienne de recherche sur la méningite
Publisher: Fondation canadienne de recherche sur la méningite

PUBLISHED: 2016 CATEGORY: Parents, Adults TYPE: External Link Your Story: The Canadian Meningitis Research Foundation

Your Story: The Canadian Meningitis Research Foundation

You can send your story to the Meningitis Research Foundation of Canada about your experience related to meningitis.

Publisher: Meningitis Research Foundation of Canada

PUBLISHED: 2015 CATEGORY: Health care providers TYPE: External Link Guillain-Barré Syndrome and Menactra Meningococcal Vaccine

Guillain-Barré Syndrome and Menactra Meningococcal Vaccine

In 1998, some research caused concern that hepatitis B vaccination might be linked with multiple sclerosis (MS), a progressive nerve disease. Numerous studies have evaluated a possible relationship between hepatitis B vaccination and MS. A large body of scientific evidence now shows that hepatitis B vaccination does not cause or worsen MS.

Corporate Authors: Centers for Disease Control and Prevention
Publisher: Centers for Disease Control and Prevention

PUBLISHED: 2015 CATEGORY: TYPE: External Link Méningite à méningocoques (OMS)

Méningite à méningocoques (OMS)

Authors: Organisation mondiale de la Santé
Corporate Authors: Organisation mondiale de la Santé
Publisher: Organisation mondiale de la Santé